InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
16 hedge funds and large institutions have $706K invested in InVivo Therapeutics Holdings Corp in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
174% more capital invested
Capital invested by funds: $258K → $706K (+$448K)
23% more funds holding
Funds holding: 13 → 16 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$152K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$151K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$92.8K |
| 4 |
Two Sigma Investments
New York
|
+$63.1K |
| 5 |
Two Sigma Advisers
New York
|
+$57.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TF
TimeScale Financial
Danvers,
Massachusetts
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $184K | +$151K | +27,667 | +183% |
|
2
BlackRock
New York
| $149K | +$22 | +4 | +0% |
|
|
3
Renaissance Technologies
New York
| $119K | +$152K | +27,725 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $73K | +$92.8K | +16,946 | New |
|
|
5
Two Sigma Investments
New York
| $49K | +$63.1K | +11,521 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $47K | +$673 | +123 | +1% |
|
|
7
Two Sigma Advisers
New York
| $45K | +$57.3K | +10,468 | New |
|
8
UBS Group
Zurich,
Switzerland
| $24K | +$30.3K | +5,539 | +553,900% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $7K | +$4.69K | +856 | +96% |
|
10
Morgan Stanley
New York
| $6K | +$1.72K | +315 | +27% |
|
|
IA
11
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
SWM
12
Sugarloaf Wealth Management
Duluth,
Georgia
| $1K | – | – | – |
|
|
TF
13
TimeScale Financial
Danvers,
Massachusetts
| – | -$5 | -1 | -50% |
|
NVIV Hedge Fund Activity: Q3 2022 in Review
16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2022, worth a combined $706K — up 174% from $258K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NVIV positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $152K. The largest seller was TimeScale Financial, cutting an estimated $5.
- 16 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2022, up from 13 in Q2 2022.
- Funds reported $706K of InVivo Therapeutics Holdings Corp stock for Q3 2022, up 174% quarter-over-quarter.
- 4 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2022 and 1 closed out, a net change of +3 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2022 was Renaissance Technologies, an estimated $152K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2022 was TimeScale Financial, an estimated $5 sold.
Based on aggregated 13F filings for Q3 2022.